No, this is not genomic. Car-T cell treatment is a form of immunotherapy. Their genomic business mainly revolves around serving clients (for example, the latest client is Eostre and other mini labs in Malaysia) and they don't develop their own technology. They use equipments from Illumina to detect genetic variation. Do not confuse both technology. Car-T cell treatment is still a highly speculative tech within the realm of biotechnology so don't expect MGRC to fly anytime soon. They have a new factory in PJ for this. And the usual genomic screening business remains in their HQ in Klang. The rest I am not too sure. But I hope they venture into the prospect of CRISPR technology and get ready for regularisation plans. They still need to improve their cash flow first
Genomic sector remains volatile despite healthy growth prospects. Sophisticated investors are advised to closely monitor current developments and scientific breakthroughs within the industry.
A US start-up has successfully treated the first patients using a Crispr gene-editing therapy directed inside the body to an internal organ. The early trial data from Intellia Therapeutics, co-founded by Nobel Prize winner Jennifer Doudna, marked a breakthrough for Crispr-based treatments, showing scientists had overcome challenges that had previously restricted the technology’s use to editing cells outside the body or in the eye. John Leonard, Intellia’s chief executive, said he was “super gratified” to see the positive results, which opened the door to treatments beyond the “tiny subset” of diseases for which Crispr-based treatments have been trialled
I can see your preference for Intellia Therapeutics. In terms of share price, it is a matter of time they will surpass that of Illumina's. MGRC isn't keen to keep their shareholders informed. There may be reasons for doing this. Any reason why?
The regularization plan will only be presented before end of 2021. What are your thoughts of the delay? Is there a tussle going on for control of the company?
wallstreetrookie Still waiting on updates for regularisation plan.
The good thing is corner up and push up to, maybe will do free warrsnt or bonus issue or share split, standard la all these no idea opeartorr and owner
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
wallstreetrookie
9,784 posts
Posted by wallstreetrookie > 2021-05-20 18:53 | Report Abuse
Also potential for cancer treatment